The increasing lifestyle use of modafinil by healthy people: Safety and ethical issues

Current Opinion in Behavioral Sciences

Volumn 4, Issue , 2015, Pages 136-141

  Porsdam Mann, Sebastian ^a   Sahakian, Barbara J ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MODAFINIL;

DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; ETHICS; GOVERNMENT; HUMAN; LIFESTYLE; PERSUASIVE COMMUNICATION; REVIEW; SOCIETY;

EID: 84935905904     PISSN: None     EISSN: 23521546     Source Type: Journal    
DOI: 10.1016/j.cobeha.2015.05.004     Document Type: Review

References (37)

1. Sattler S., Mehlkop G., Graeff P., Sauer C. Evaluating the drivers of and obstacles to the willingness to use cognitive enhancement drugs: the influence of drug characteristics, social environment, and personal characteristics. Subst Abuse Treat Prev Policy 2014, 9:8.
2. Minzenberg M.J., Carter C.S. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology 2008, 33:1477-1502.
3. Volkow N.D., Fowler J.S., Logan J., Alexoff D., Zhu W., Telang F., Wang G.J., Jayne M., Hooker J.M., Wong C., et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA 2009, 301:1148-1154.
4. Scoriels L., Jones P.B., Sahakian B.J. Modafinil effects on cognition and emotion in schizophrenia and its neurochemical modulation in the brain. Neuropharmacology 2012, 64:168-184.
5. Lyons T.J., French J. Modafinil: the unique properties of a new stimulant. Aviat Space Environ Med 1991, 62:432-435.
6. Food and Drug Administration Medication guide: Provigil 2010, [Online] http://www.fda.gov/downloads/Drugs/DrugSafety/UCM231722.pdf.
7. Dresler M., Sandberg A., Ohla K., Bublitz C., Trenado C., Mroczko-Wasowicz A., Kühn S., Repantis D. Non-pharmacological cognitive enhancement. Neuropharmacology 2013, 64:529-543.
8. Davies M., Wilton L., Shakir S. Safety profile of modafinil across a range of prescribing indications, including off-label use, in a primary care setting in England: results of a modified prescription-event monitoring study. Drug Saf 2013, 36:237-246.
9. Normann C., Berger M. Neuroenhancement: status quo and perspectives. Eur Arch Psychiatry Clin Neurosci 2008, 258:110-114.
10. Vastag B. Poised to challenge need for sleep, wakefulness enhancer rouses concerns. JAMA 2004, 291:167-170.
11. Turner D.C., Robbins T.W., Clark L., Aron A.R., Dowson J., Sahakian B.J. Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology (Berl) 2003, 165:260-269.
12. Müller U., Rowe J.B., Rittman T., Lewis C., Robbins T.W., Sahakian B.J. Effects of modafinil on non-verbal cognition, task enjoyment and creative thinking in healthy volunteers. Neuropharmacology 2013, 64:490-495.
13. Stoops W.W., Lile J.A., Fillmore M.T., Glaser P.E., Rush C.R. Reinforcing effects of modafinil: influence of dose and behavioral demands following drug administration. Psychopharmacology (Berl) 2005, 182:186-193.
14. Caldwell J.A., Caldwell J.L., Smith J.K., Brown D.L. Modafinil's effects on simulator performance and mood in pilots during 37h without sleep. Aviat Space Environ Med 2004, 75:777-778.
15. Repantis D., Schlattmann P., Laisney O., Heuser I. Modafinil and methylphenidate for neuroenhancement in healthy individuals: a systematic review. Pharmacol Res 2010, 62:187-206.
16. Russo M.B., Arnett M.V., Thomas M.L., Caldwell J.A. Ethical use of cogniceuticals in the militaries of democratic nations. Am J Bioeth 2008, 8:39-41.
17. Maher B. Poll results: look who's doping. Nature 2008, 452:674-675.
18. Smith M.E., Farah M.J. Are prescription stimulants smart pills? The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals. Psychol Bull 2011, 7(137):7-741.
19. Gill M., Haerich P., Westcott K., Godenick K.L., Tucker J.A. Cognitive performance following modafinil versus placebo in sleep-deprived emergency physicians: a double-blind randomized crossover study. Acad Emerg Med 2006, 13:158-165.
20. Sugden C., Housden C.R., Aggarwal R., Sahakian B.J., Darzi A. Effect of pharmacological enhancement on the cognitive and clinical psychomotor performance of sleep-deprived doctors: a randomized controlled trial. Ann Surg 2012, 255:222-227.
21. Weingart S.N., Wilson R.M., Gibberd R.W., Harrison B. Epidemiology of medical error. Br Med J 2000, 320:774-777.
22. Sagberg F. Road accidents caused by drivers falling asleep. Accid Anal Prev 1999, 31:639-649.
23. Sandberg A., Sinnott-Armstrong W., Savulescu J. Cognitive enhancement in courts. Oxford Handbook of Neuroethics 2011, 273-284. Oxford University Press. B.J. Sahakian, J. Illes (Eds.).
24. Getsios D., Blume S., Ishak K.J., Maclaine G., Hernández L. An economic evaluation of early assessment for Alzheimer's disease in the United Kingdom. Alzheimers Dement 2012, 8:22-30.
25. Carstairs S.D., Urquhart A., Hoffman J., Clark R.F., Cantrell F.L. A retrospective review of supratherapeutic modafinil exposures. J Med Toxicol 2010, 6:307-310.
26. Swanson J.M., Greenhill L.L., Lopez F.A., Sedillo A., Earl C.Q., Jiang J.G., Biederman J. Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder. Results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation. J Clin Psychiatry 2006, 67:137-147.
27. Cephalon Inc Modafinil (CEP-1538) tablets supplemental NDA 20-717/S-019 ADHD indication: briefing document for Psychopharmacologic Drugs Advisory Committee Meeting 2006, Cephalon Inc, Frazer, PA.
28. Rugino T. A review of modafinil film-coated tablets for attention-deficit/hyperactivity disorder in children and adolescents. Neuropsychiatr Dis Treat 2007, 3:293-301.
29. President's Council on Bioethics Beyond Therapy: Biotechnology and the Pursuit of Happiness 2011, Regan Books.
30. Presidential Commission for the Study of Bioethics GRAY MATTERS - Integrative Approaches for Neuroscience, Ethics, and Society 2014, http://www.bioethics.gov/sites/default/files/Gray%20Matters%20Vol%201.pdf.
31. Ethical considerations of neuroscience research and the application of neuroscience research findings for the Presidential Commission for the Study of Bioethical Issues. J Law Biosci 2014, 1-6.
32. Franke A.G., Bonertz C., Christmann M., Engeser S., Lieb K. Attitudes toward cognitive enhancement in users and nonusers of stimulants for cognitive enhancement: a pilot study. AJOB Prim Res 2012, 3:48-57.
33. Zohar J., Stahl S.M., Moller H.-J., Blier P., Kupfer D.J., Yamawaki S. Neuroscience-based Nomenclature 2014, the Taskforce, consisting of representatives from ACNP, AsCNP, CINP, ECNP, and IUPHAR, http://www.ecnp.eu/~/media/Files/ecnp/Projects%20and%20initiatives/Nomenclature/Review%20articleNEUPSY_10717v2%20pdf.pdf.
34. Hyman S. Cognitive enhancement: promises and perils. Neuron 2011, 69:595-598.
35. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998, 105:31S-38S.
36. Husain M., Mehta M.A. Cognitive enhancement by drugs in health and disease. Trends Cogn Sci 2010, 15:28-36.
37. The Joint Academies Report Human enhancement and the future of work 2012, https://royalsociety.org/~/media/Royal_Society_Content/policy/projects/human-enhancement/2012-11-06-Human-enhancement.pdf.